Abstract
Breast cancer is the most common cancer diagnosis worldwide accounting for 1 out of every 8 cancer diagnoses. The elevated expression of Thymidine Kinase 1 (TK1) is associated with more aggressive tumor grades, including breast cancer. Recent studies indicate that TK1 may be involved in cancer pathogenesis; however, its direct involvement in breast cancer has not been identified. Here, we evaluate potential pathogenic effects of elevated TK1 expression by comparing HCC 1806 to HCC 1806 TK1-knockdown cancer cells (L133). Transcriptomic profiles of HCC 1806 and L133 cells showed cell cycle progression, apoptosis, and invasion as potential pathogenic pathways affected by TK1 expression. Subsequent in-vitro studies confirmed differences between HCC 1806 and L133 cells in cell cycle phase progression, cell survival, and cell migration. Expression comparison of several factors involved in these pathogenic pathways between HCC 1806 and L133 cells identified p21 and AKT3 transcripts were significantly affected by TK1 expression. Creation of a protein-protein interaction map of TK1 and the pathogenic factors we evaluated predict that the majority of factors evaluated either directly or indirectly interact with TK1. Our findings argue that TK1 elevation directly increases HCC 1806 cell pathogenicity and is likely occurring by p21- and AKT3-mediated mechanisms to promote cell cycle arrest, cellular migration, and cellular survival.
Publisher
Public Library of Science (PLoS)
Reference100 articles.
1. Nucleic acid metabolism in regenerating rat liver. VI. Soluble enzymes which convert thymidine to thymidine phosphates and DNA;FJ Bollum;Cancer research,1959
2. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage;YL Chen;The Journal of biological chemistry,2010
3. Human thymidine kinase 1. Regulation in normal and malignant cells;B Munch-Petersen;Advances in enzyme regulation,1995
4. The role of thymidine kinase in cancer diseases;O Topolcan;Expert Opinion on Medical Diagnostics,2008
5. The proliferation marker thymidine kinase 1 in clinical use;J Zhou;Mol Clin Oncol,2013